ACADIA Pharmaceuticals (LTS:0A4W) EPS (Basic): $2.23 (TTM As of Mar. 2026)


LTS:0A4W ACADIA Pharmaceuticals Inc LTS:0A4W
76 GF Score
Price $26.87
GF Value $28.78
! 8 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals EPS (Basic)?

ACADIA Pharmaceuticals LTS:0A4W 76 EPS (Basic) is $2.23 as of Mar. 2026. GuruFocus rates LTS:0A4W with a GF Score™ of 76/100 and a GF Value™ of $28.78. The stock has 8 warning signs investors should review.

ACADIA Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $0.02. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $2.23.

ACADIA Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2026 was $0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $2.20.

ACADIA Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2026 was $0.02. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 2.20.

During the past 12 months, ACADIA Pharmaceuticals's average EPS without NRIGrowth Rate was 60.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, ACADIA Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 40.90% per year. The lowest was -74.60% per year. And the median was 8.80% per year.

ACADIA Pharmaceuticals  (LTS:0A4W) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

ACADIA Pharmaceuticals EPS (Basic) Related Terms

ACADIA Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals EPS (Basic) Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.05 -1.34 -0.37 1.37 2.32

ACADIA Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.16 0.43 1.62 0.02
LTS:0A4W
76GF Score
ACADIA Pharmaceuticals Inc LTS:0A4W
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

ACADIA Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(391-0)/168.356
=2.32

ACADIA Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(3.637-0)/170.517
=0.02

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $2.23 mean?
ACADIA Pharmaceuticals (LTS:0A4W) has a EPS (Basic) of $2.23 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' EPS (Basic) too high?
ACADIA Pharmaceuticals' current EPS (Basic) is $2.23. Overall, ACADIA Pharmaceuticals has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' EPS (Basic) compare to EWTX and CRNX?
ACADIA Pharmaceuticals' EPS (Basic) of $2.23 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current EPS (Basic) is $2.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
ACADIA Pharmaceuticals (LTS:0A4W) has a current EPS (Basic) of $2.23. The stock's GF Value™ is $28.78, compared to a current price of $26.87 — trading 6.6% below its estimated fair value. The current EPS (Basic) is $2.23. ACADIA Pharmaceuticals' overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For ACADIA Pharmaceuticals (LTS:0A4W), the current EPS (Basic) is $2.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (LTS:0A4W) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be undervalued. The current stock price of $26.87 is trading 6.6% below its estimated GF Value™ of $28.78.

Key valuation signals for LTS:0A4W:

  • EPS (Basic): $2.23
  • GF Value™: $28.78 vs. price of $26.87 (6.6% below fair value)
  • GF Score™: 76/100 with 8 warning signs

No single metric tells the full story. See the LTS:0A4W stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
76GF Score

Get the complete analysis for LTS:0A4W

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.87
Price
$28.78
GF Value